Related Experiment Videos
Moricizine-induced proarrhythmia
1Department of Clinical Cardiac Electrophysiology, Marquette General Hospital, Michigan, USA.
Clinical Cardiology
|November 1, 1992
Summary
Moricizine, a Class I antiarrhythmic, may cause life-threatening proarrhythmia, contrary to previous assumptions. This cardiac arrhythmia risk highlights the need for caution, especially in patients with structural heart disease.
Area of Science:
- Pharmacology
- Cardiology
Background:
- Moricizine is a Class I antiarrhythmic drug approved for life-threatening ventricular arrhythmias.
- Previous studies suggested a low proarrhythmic potential for moricizine.
- The drug was notably studied in the Cardiac Arrhythmia Suppression Trial.
Observation:
- A case of life-threatening late proarrhythmia caused by moricizine is reported.
- The authors share their clinical experience with moricizine.
Findings:
- Moricizine demonstrates a significant proarrhythmic potential.
- This potential can manifest as late-onset arrhythmias.
Implications:
- Moricizine should not be used empirically for ventricular ectopy.
- Caution is advised when prescribing moricizine, particularly in patients with underlying structural heart disease.
- Clinical use of moricizine requires careful risk-benefit assessment due to its proarrhythmic effects.